A Phase 1, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-7342 in Subjects With Obesity or Overweight
Latest Information Update: 13 Jan 2026
At a glance
- Drugs SGB 7342 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors SanegeneBio
Most Recent Events
- 13 Jan 2026 New trial record